Thromboses-prone drugs, administration days, single and cumulative doses according to different ALL-induction protocols are shown. In the BFM-95 protocol (*) DNR was administered twice (days 8 and 15), and in the 2000 study on days 8, 15, 22, and 29. In addition, in the BFM 2000 protocol PDN and DEXA were randomized. In the FRALLE 2000 HRG (dashed arrow), children received PDN instead of DEXA, and ASP was started on day 8 instead of day 10. ALL indicates acute lymphoblastic leukemia; ASP, Escherichia coli asparaginase; D, day; DEXA, dexamethasone; DNR, daunorubicin; HR, high risk; PDN, prednisone; SR, standard risk; and VCR, vincristine.